Trial DesignComparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
Section snippets
Background
Dual therapy with aspirin and the thienopyridine clopidogrel is a standard treatment in patients with acute coronary syndromes (ACS) with or without ST-segment elevation and after stent procedures.1, 2, 3 However, approximately 15% to 48% of patients have a poor platelet inhibition response to clopidogrel,4, 5, 6, 7, 8 a factor that contributes to a residual high risk of recurrent events.7
Clopidogrel is a prodrug that requires 2-step metabolism for conversion to its active metabolite, which
Study objectives
The primary objective of PLATO (D5130C05262) is to test the hypothesis that ticagrelor is superior to clopidogrel for the prevention of vascular events (death from vascular causes, MI, or stroke) in patients with non–ST-elevation ACS or ST-elevation ACS.
The primary efficacy variable is time to first occurrence of any event from the composite of death from vascular causes, MI, or stroke. The rationale for choosing this composite end point was to use the most unbiased estimate of the effect
Study design and organization
The PLATO trial is a phase III multicenter randomized, double-blind, double-dummy, parallel-group, event-driven, international trial of approximately 18,000 patients hospitalized because of ACS. Patients are randomized to receive ticagrelor or clopidogrel in a 1:1 ratio using a randomization schedule blocked by site. Randomization must take place within 24 hours of onset of the most recent cardiac ischemic symptoms and before any planned or urgent PCI. Initial background assessments include
Patient population
The PLATO study involves >18,000 patients recruited from approximately 800 sites in 43 countries. The primary enrollment criteria state that a patient must be ≥18 years and hospitalized with documented evidence of non–ST-elevation or ST-elevation ACS in the 24 hours before randomization. Inclusion and exclusion criteria details are shown in Table I, Table II. Patients with ST-elevation ACS treated with fibrinolysis will be excluded because of lack of safety data with this combination of
Treatment regimens and concomitant medications
Patients are randomly assigned to oral maintenance treatment with ticagrelor 90 mg twice daily plus placebo (matched to clopidogrel) or clopidogrel 75 mg once daily plus placebo (matched to ticagrelor) as early as possible after the index event and not >24 hours postevent. The ticagrelor 90 mg dose was chosen because it is well tolerated and produces significantly greater IPA than clopidogrel 75 mg.15, 16 Patients randomized to ticagrelor receive a loading dose of 180 mg (two 90 mg tablets) of
Efficacy
Sample size is based on an expected primary composite efficacy end point (death from vascular causes, MI, or stroke) event rate of 11% in the clopidogrel group over 12 months. This expected rate was based on the rate of 9.3% over an average of 9 months in the CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) study4 and by an event rate of 12% in ST-elevation ACS with primary PCI over a 6- to 18-month treatment period.2 It is assumed that the hazard rate of an event in the
Present status
The first patient was enrolled in October 2006. By July 1, 2008, >18,000 patients had been enrolled; and enrollment ceased in mid-July 2008. The Holter program was ended according to the protocol in November 2007. The DSMB reviewed the emerging data on patient safety after enrollment of 12,889 patients in March 2008 and recommended continuation of enrollment without protocol alterations and that further follow-up on safety laboratory testing was not necessary. The statement to continue the
Conclusion
The PLATO trial includes a broad ACS patient population recruited as early as possible after admission to the hospital, including patients with and without ST-segment elevation and those managed early invasively and conservatively. The trial includes currently recommended doses of clopidogrel, including the 600-mg loading dose, and initiation of therapy before PCI.20 The protocol also allows clopidogrel-exposed patients, both as maintenance treatment and loading dose. Therefore, the trial will
References (20)
- et al.
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non–ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial
J Am Coll Cardiol
(2007) - et al.
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes
J Am Coll Cardiol
(2007) EuroQol: the current state of play
Health Policy
(1996)- et al.
Guidelines for the diagnosis and treatment of non–ST-segment elevation acute coronary syndromes
Eur Heart J
(2007) - et al.
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Eur Heart J
(2005) - et al.
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
N Engl J Med
(2005) - et al.
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
N Engl J Med
(2001) - et al.
Prasugrel achieves greater and faster P2Y12 receptor–mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Eur Heart J
(2008) - et al.
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
Eur Heart J
(2006) - et al.
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
Circulation
(2004)
Cited by (366)
Comparison of Ticagrelor and Clopidogrel in Patients With Acute Coronary Syndrome at High Bleeding or Ischemic Risk
2024, American Journal of CardiologyMorbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical Trials
2023, Journal of Cardiac FailureAge- and Sex-Specific Disparities in Outcomes After Ticagrelor Versus Clopidogrel in East Asian Patients
2023, American Journal of CardiologyDe-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy?
2023, European Journal of Internal Medicine
Randomized Clinical Trial #: NCT00391872.
Dr. Raymond J. Gibbons served as guest editor for this manuscript.